» Articles » PMID: 2930692

Prognostic Factors in High and Intermediate Grade Non-Hodgkin's Lymphoma

Overview
Journal Br J Cancer
Specialty Oncology
Date 1989 Feb 1
PMID 2930692
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

An analysis of prognostic factors has been performed on 260 patients with high and intermediate grade non-Hodgkin's lymphoma (NHL) treated over an 11-year period between 1975 and 1986. The overall 5-year survival rate was 50% with a median follow-up of 72 months. Over 20 clinical, radiological and laboratory parameters have been studied, including variables reported to be important indicators of prognosis in previous series, and these variables have been subjected to univariate and multivariate analysis. Attainment of complete remission (CR) was the most important predictor of overall survival, low serum lactate dehydrogenase (LDH), limited stage disease and a high serum albumin were also independently associated with prolonged survival in multivariate analysis. After removing remission status from the model, Ann Arbor clinical stage became the most significant pre-treatment prognostic indicator. Sixty-five per cent of patients achieved CR, and a discriminant analysis showed that failure to attain CR was associated with advanced stage disease, constitutional symptoms, increasing patient age, a low serum albumin and the presence of bulk disease. Advanced clinical stage and an elevated serum LDH predicted independently for a poor relapse-free survival, and reduced overall survival following CR. There was no significant correlation between histological subtype in the Kiel classification and prognosis. This study confirms the prognostic significance of remission status and Ann Arbor clinical stage, and illustrates additional factors including serum levels of albumin and LDH, which serve to enhance the pre-treatment prognostic evaluation of patients with unfavourable histology NHL.

Citing Articles

Non-Hodgkin Lymphoma Metabolism.

Kirsch B, Chang S, Betenbaugh M, Le A Adv Exp Med Biol. 2021; 1311:103-116.

PMID: 34014537 PMC: 9703228. DOI: 10.1007/978-3-030-65768-0_7.


Non-Hodgkin Lymphoma Metabolism.

Kirsch B, Chang S, Le A Adv Exp Med Biol. 2018; 1063:95-106.

PMID: 29946778 DOI: 10.1007/978-3-319-77736-8_7.


Serum Lactate Dehydrogenase in Non-Hodgkin's Lymphoma: A Prognostic Indicator.

Yadav C, Ahmad A, DSouza B, Agarwal A, Nandini M, Ashok Prabhu K Indian J Clin Biochem. 2016; 31(2):240-2.

PMID: 27069334 PMC: 4820421. DOI: 10.1007/s12291-015-0511-3.


Colorectal lymphoma.

Quayle F, Lowney J Clin Colon Rectal Surg. 2009; 19(2):49-53.

PMID: 20011310 PMC: 2780105. DOI: 10.1055/s-2006-942344.


Diffuse large B-cell lymphoma: experience from a tertiary care center in North India.

Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R Med Oncol. 2009; 27(2):310-8.

PMID: 19350421 DOI: 10.1007/s12032-009-9211-2.


References
1.
BIERMAN H, Hill B, Reinhardt L, EMORY E . Correlation of serum lactic dehydrogenase activity with the clinical status of patients with cancer, lymphomas, and the leukemias. Cancer Res. 1957; 17(7):660-7. View

2.
Nathwani B, Dixon D, Jones S, HARTSOCK R, REBUCK J, Byrne Jr G . The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group. Blood. 1982; 60(5):1068-74. View

3.
Ferraris A, Giuntini P, Gaetani G . Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979; 54(4):928-32. View

4.
Sweet D, Golomb H, Ultmann J, Miller J, Stein R, Lester E . Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med. 1980; 92(6):785-90. DOI: 10.7326/0003-4819-92-6-785. View

5.
Blackledge G, Bush H, Chang J, Crowther D, Deakin D, DODGE O . Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group). Eur J Cancer (1965). 1980; 16(11):1459-68. DOI: 10.1016/0014-2964(80)90056-0. View